Topic: cardiovascular disease
The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.
Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.
Pfizer has set up a new partnering network to try to foster collaborations with top-tier universities
KBP Biosciences has raised $76 million as it eyes a new headquarters in the U.S. and a new chief executive in the form of ex-GSK vet Brian McVeigh.
The technology is designed to support the performance and interpretation of echocardiograms.
Idorsia spun out of Actelion before it was taken over by J&J earlier this year, but it will still play a big part in one of its lead products.
The Big Pharma reached the decision after going over a mixed set of data from its big bet on a phase 3 program.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
Akcea sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome to market in the U.S. next year.
The Philips-HeartFlow deal follows earlier agreements with GE Healthcare and Siemens Healthineers.